Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe

Autor: G. Comi, Patrick Vermersch, Carlo Pozzilli, B. Tackenberg, P. S. Soerensen, Gilles Edan, H.-P. Hartung, M. Delvecchio, Ludwig Kappos, Oscar Fernández, G. Gionvannoni, Sten Fredrikson, Eva Havrdova

Publikováno v: European Journal of Neurology
European Journal of Neurology, Wiley, 2017, 24 (3), pp.516-522. ⟨10.1111/ene.13236⟩
European Journal of Neurology, 2017, 24 (3), pp.516-522. ⟨10.1111/ene.13236⟩

International audience; Background and purpose - Up-to-date information is needed on the extent to which neurologists treating multiple sclerosis (MS) in Europe are integrating rapidly evolving diagnostic criteria, disease-modifying therapies and rec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af08644f8767c50b30c07da25050d382
https://doi.org/10.1111/ene.13236

Terminal complement activation is increased and associated with disease severity in CIDP

Autor: B. Tackenberg, Jan D. Lünemann, Falk Hiepe, Christian W. Keller, Isaak Quast

Publikováno v: Annals of Clinical and Translational Neurology

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic autoimmune neuropathy. While both cell‐mediated and humoral mechanisms contribute to its pathogenesis, the rapid clinical response to plasmapheresis implicates a ci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9692dce794367806d27605a17decb933
https://doi.org/10.1002/acn3.331

Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie

Autor: B. Hemmer, R. Gold, Aiden Haghikia, U. Meier, Martin Stangel, Friedemann Paul, M. Lang, Anke Salmen, Tjalf Ziemssen, Martin S. Weber, P. Flachenecker, Volker Limmroth, T. Kümpfel, B. Tackenberg, S. G. Meuth, Frauke Zipp, Andrew T. Chan, Ralf A. Linker, Reinhard Hohlfeld, Heinz Wiendl, Thomas Korn, A. Berthele, Hayrettin Tumani, Kerstin Hellwig, Wolfgang Brück, Luisa Klotz, Clemens Warnke

Publikováno v: Der Nervenarzt. 87:645-659

With the approval of various substances for the immunotherapy of multiple sclerosis (MS), treatment possibilities have improved significantly over the last few years. Indeed, the choice of individually tailored preparations and treatment monitoring f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1841ce09d0688347bb9dacacabcc6979
https://doi.org/10.1007/s00115-016-0077-1